MedTrace Logo

Varithena Versus Endothermal Ablation of the Great Saphenous Vein (VERITAS)

NCT05312970 · Status: TERMINATED · Phase: PHASE4 · Type: INTERVENTIONAL · Enrollment: 43

Last updated 2026-03-20

Study results available
· View outcomes & findings →

Summary

The purpose of this study is to observe insights into the benefits of Varithena compared to Endothermal Ablation (ETA) in the treatment of the great saphenous vein.

Conditions

  • Varicose Veins

Interventions

DEVICE

FDA-approved Endothermal Ablation (ETA) systems

FDA-approved ETA systems, including Radiofrequency ablation (RFA) systems or Endovenous laser ablation (EVLA) systems.

DRUG

Varithena®

Varithena® (polidocanol injectable foam) 1%

Sponsors & Collaborators

  • Boston Scientific Corporation

    lead INDUSTRY

Study Design

Allocation
RANDOMIZED
Purpose
OTHER
Masking
NONE
Model
PARALLEL

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2023-02-10
Primary Completion
2024-04-04
Completion
2024-04-04
FDA Drug
Yes
FDA Device
Yes

Countries

  • United States

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT05312970 on ClinicalTrials.gov